Endocrinología

The New England Journal of Medicine

Nov 2023

Lee más sobre Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

Journal of Hepatology
Junio 2024

Lee más sobre EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)

The New England Journal of Medicine

Junio 2024

Lee más sobre Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis

The New England Journal of Medicine

Junio 2024

Lee más sobre Magnesium Disorders

The New England Journal of Medicine

Junio 2024

Lee más sobre Magnesium Disorders

The Lancet

Junio 24

Lee más sobre [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, pha

Cardiovascular Research, Volume 119, Issue 18, December 2023, Pages 2825–2842,

Lee más sobre New therapies for obesity

November 23, 2023
N Engl J Med 2023; 389:1979-1991

Lee más sobre Postmenopausal Osteoporosis

Maturitas

Oct 2023

Lee más sobre EMAS position statement: Testosterone replacement therapy in older men

Arch Med Sci 2023;19(6)

Lee más sobre 2023: The year in cardiovascular disease - the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?

Suscribirse a Endocrinología

Agenda

Septiembre 2024

Lun	Mar	Mié	Jue	Vie	Sáb	Dom
26	27	28	29	30	31	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	1	2	3	4	5	6

Síguenos

Top